Platinum compounds

Carboplatin

• Solution for infusion vials 10mg/1ml

Notes

1. NICE TA284 : Bevacizumab (Avastin) in combination with paclitaxel and carboplatin is not recommended for first-line treatment of advanced ovarian cancer (International Federation of Gynaecology and Obstetrics [FIGO] stages IIIB, IIIC and IV epithelial ovarian, fallopian tube or primary peritoneal cancer) (May 2013)
2. NICE TA285: Bevacizumab (Avastin) in combination with gemcitabine and carboplatin is not recommended for treating people with the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents (May 2013)

Cisplatin

• Solution for infusion vials 1mg/1ml

Oxaliplatin

• Solution for infusion vials 5mg/1ml

Notes

1. NICE TA100: Oxaliplatin in combination with 5-fluorouracil and folinic acid is recommended an option for the adjuvant treatment of patients with stage III (Duke's C) colon cancer following surgery for the condition (April 2006)